Is there a difference in triglyceride reduction between atorvastatin and rosuvastatin?

Triglyceride Reduction: Rosuvastatin vs Atorvastatin

Rosuvastatin produces modestly greater triglyceride reductions compared to atorvastatin at equivalent doses, though both statins effectively lower triglycerides in clinical practice. 1

Comparative Triglyceride-Lowering Effects

High-Intensity Dose Comparison

• Rosuvastatin 20-40 mg reduces triglycerides by approximately 28% in hypercholesterolemic patients, compared to atorvastatin 40-80 mg 1
• At maximal doses (rosuvastatin 40 mg vs atorvastatin 80 mg), both statins produce similar triglyceride reductions of approximately 24-33%, with no statistically significant difference between them 2
• A 2025 meta-analysis demonstrated rosuvastatin reduced triglycerides by 31.98 mg/dL compared to atorvastatin's 24.76 mg/dL reduction, showing rosuvastatin's superior effect 3

Moderate-Intensity Dose Comparison

• In patients with hypertriglyceridemia (TG ≥177 mg/dL), rosuvastatin 10 mg produced significantly greater triglyceride reductions than atorvastatin 10 mg 4
• Rosuvastatin 20 mg and 40 mg resulted in triglyceride reductions similar to equal doses of atorvastatin in hypertriglyceridemic patients 4
• Mean triglyceride reductions across statin doses ranged from 15.1% to 31.3%, with the magnitude dependent on both statin choice and dose 4

Clinical Implications

Practical Dosing Algorithm

• For patients requiring high-intensity statin therapy with elevated triglycerides, start with rosuvastatin 20 mg (achieving ~28% TG reduction) or atorvastatin 40 mg 1
• If triglyceride reduction is inadequate after 4-6 weeks, escalate to rosuvastatin 40 mg or atorvastatin 80 mg, which produce comparable triglyceride-lowering effects 2
• Both statins at maximal doses reduce apolipoprotein B-48 (intestinal lipoproteins) and remnant lipoprotein cholesterol similarly, by approximately 32-38% and 59-62% respectively 2

Additional HDL Benefits

• Rosuvastatin produces significantly greater HDL-C increases (up to 14%) compared to atorvastatin at higher doses, which may provide additional cardiovascular benefit beyond triglyceride lowering 1
• The 2025 meta-analysis confirmed rosuvastatin increased HDL by 3.87 mg/dL versus atorvastatin's 1.85 mg/dL increase 3

Important Caveats

Renal Function Considerations

• In patients with severe renal impairment (CrCl <30 mL/min), atorvastatin is preferred as it requires no dose adjustment, whereas rosuvastatin should not exceed 10 mg daily 1
• This renal dosing limitation may affect the comparative triglyceride-lowering efficacy in patients with kidney disease 1

Residual Risk Management

• Triglyceride reduction with statins alone (15-31%) is numerically less than LDL-C reduction (40-55%), and additional triglyceride-lowering therapy may be needed to further reduce residual cardiovascular risk 4
• If LDL-C goals are not achieved within 4-6 weeks, immediately add ezetimibe to the statin regimen rather than relying on statin monotherapy 5